Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Metastases, Brain, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 11 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2018 — May 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aarhus, Denmark , Aberdeen, United Kingdom , Anaheim, United States , Angers, France , Antwerp, Belgium , Arkhangelsk, Russia , Athens, Greece , Avignon, France , Bangkok, Thailand and 135 more locations